Works matching IS 25233548 AND DT 2023 AND VI 43 AND IP 1

Results: 11

circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer.

Published in:

Cancer Communications, 2023, v. 43, n. 1, p. 100, doi. 10.1002/cac2.12380

By:

Yang, Yufei;
Luo, Dakui;
Shao, Yang;
Shan, Zezhi;
Liu, Qi;
Weng, Junyong;
He, Weijing;
Zhang, Ruoxin;
Li, Qingguo;
Wang, Ziliang;
Li, Xinxiang

Publication type:

Article

Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives.

Published in:

Cancer Communications, 2023, v. 43, n. 1, p. 3, doi. 10.1002/cac2.12392

By:

Fang, Zengli;
Meng, Qingcai;
Xu, Jin;
Wang, Wei;
Zhang, Bo;
Liu, Jiang;
Liang, Chen;
Hua, Jie;
Zhao, Yingjun;
Yu, Xianjun;
Shi, Si

Publication type:

Article

Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21‐mediated ubiquitination/degradation of STAT1 in a GTP binding‐dependent modality.

Published in:

Cancer Communications, 2023, v. 43, n. 1, p. 123, doi. 10.1002/cac2.12386

By:

Zhang, Lu;
Li, Qingya;
Yang, Jing;
Xu, Penghui;
Xuan, Zhe;
Xu, Jianghao;
Xu, Zekuan

Publication type:

Article

p21 is necessary for the beneficial effects of fasting during chemotherapy.

Published in:

Cancer Communications, 2023, v. 43, n. 1, p. 164, doi. 10.1002/cac2.12384

By:

Plaza, Adrián;
Pastor‐Fernández, Andrés;
López‐Aceituno, José L.;
Barradas, Marta;
Pantoja, Cristina;
Fernandez‐Marcos, Pablo J.

Publication type:

Article

Lysosomal TMEM9‐LAMTOR4‐controlled mTOR signaling integrity is required for mammary tumorigenesis.

Published in:

Cancer Communications, 2023, v. 43, n. 1, p. 159, doi. 10.1002/cac2.12382

By:

Zhang, Shengzhe;
Lee, Sung Ho;
Nie, Litong;
Huang, Yuanjian;
Zou, Gengyi;
Jung, Youn‐Sang;
Jun, Sohee;
Zhang, Jie;
Lien, Esther M.;
Chen, Junjie;
Park, Jae‐Il

Publication type:

Article

Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?

Published in:

Cancer Communications, 2023, v. 43, n. 1, p. 75, doi. 10.1002/cac2.12393

By:

Feng, Ruimei;
Su, Qingling;
Huang, Xiaoyin;
Basnet, Til;
Xu, Xin;
Ye, Weimin

Publication type:

Article

A phase Ib/II study of fruquintinib in combination with paclitaxel as the second‐line therapy for advanced gastric cancer.

Published in:

Cancer Communications, 2023, v. 43, n. 1, p. 150, doi. 10.1002/cac2.12379

By:

Zhang, Yang;
Wang, Zi‐Xian;
Shen, Lin;
Li, Jin;
Huang, Jing;
Su, Wei‐Guo;
Zhang, Dong‐Sheng;
Xu, Rui‐Hua

Publication type:

Article

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.

Published in:

Cancer Communications, 2023, v. 43, n. 1, p. 42, doi. 10.1002/cac2.12377

By:

Yang, Hang;
Zhou, Xinyi;
Fu, Dongliang;
Le, Chenqin;
Wang, Jiafeng;
Zhou, Quan;
Liu, Xiangrui;
Yuan, Ying;
Ding, Kefeng;
Xiao, Qian

Publication type:

Article

Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‐3 study.

Published in:

Cancer Communications, 2023, v. 43, n. 1, p. 87, doi. 10.1002/cac2.12375

By:

Nikšić, Maja;
Minicozzi, Pamela;
Weir, Hannah K;
Zimmerman, Heather;
Schymura, Maria J;
Rees, Judith R;
Coleman, Michel P;
Allemani, Claudia

Publication type:

Article

Cell models with inducible oncogenic translocations allow to evaluate the potential of drugs to favor secondary translocations.

Published in:

Cancer Communications, 2023, v. 43, n. 1, p. 154, doi. 10.1002/cac2.12370

By:

Shmakova, Anna;
Lomov, Nikolai;
Viushkov, Vladimir;
Tsfasman, Tatyana;
Kozhevnikova, Yana;
Sokolova, Darina;
Pokrovsky, Vadim;
Syrkina, Marina;
Germini, Diego;
Rubtsov, Mikhail;
Vassetzky, Yegor

Publication type:

Article

Issue Information.

Published in:: Cancer Communications, 2023, v. 43, n. 1, p. 1, doi. 10.1002/cac2.12298
Publication type:: Article